Literature DB >> 11792860

Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity.

Ali Khoshnan1, Jan Ko, Paul H Patterson.   

Abstract

We have generated eight mAbs (MW1-8) that bind the epitopes polyglutamine (polyQ), polyproline (polyP), or the C terminus of exon 1 in huntingtin (htt) protein. In the brains of Huntington's disease (HD) mouse models, the anti-polyQ mAbs bind to various cytoplasmic compartments, whereas the anti-polyP and anti-C terminus mAbs bind nuclear inclusions containing htt. To use these mAbs as intracellular perturbation agents, we have cloned and expressed the antigen-binding domains of three of the mAbs as single-chain variable region fragment Abs (scFvs). In 293 cells cotransfected with htt exon 1 containing an expanded polyQ domain, MW1, MW2, and MW7 scFvs colocalize with htt exon 1. Moreover, these scFvs coimmunoprecipitate with htt exon 1 in cell extracts. In perturbation experiments, MW7 scFv, recognizing the polyP domains of htt, significantly inhibits aggregation as well as the cell death induced by mutant htt protein. In contrast, MW1 and MW2 scFvs, recognizing the polyQ stretch, stimulate htt aggregation and apoptosis. Therefore, these anti-htt scFvs can be used to investigate the role of the polyP and polyQ domains in HD pathogenesis, and antibody binding to the polyP domain has potential therapeutic value in HD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792860      PMCID: PMC117420          DOI: 10.1073/pnas.022631799

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.

Authors:  J M Lecerf; T L Shirley; Q Zhu; A Kazantsev; P Amersdorfer; D E Housman; A Messer; J S Huston
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

2.  Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.

Authors:  F C Nucifora ; M Sasaki; M F Peters; H Huang; J K Cooper; M Yamada; H Takahashi; S Tsuji; J Troncoso; V L Dawson; T M Dawson; C A Ross
Journal:  Science       Date:  2001-03-23       Impact factor: 47.728

Review 3.  Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases.

Authors:  M Y Sherman; A L Goldberg
Journal:  Neuron       Date:  2001-01       Impact factor: 17.173

Review 4.  Stability engineering of antibody single-chain Fv fragments.

Authors:  A Wörn; A Plückthun
Journal:  J Mol Biol       Date:  2001-02-02       Impact factor: 5.469

5.  Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation.

Authors:  S Waelter; A Boeddrich; R Lurz; E Scherzinger; G Lueder; H Lehrach; E E Wanker
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

6.  Expression and purification of general transcription factors by FLAG epitope-tagging and peptide elution.

Authors:  C M Chiang; R G Roeder
Journal:  Pept Res       Date:  1993 Mar-Apr

7.  New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins.

Authors:  J Ko; S Ou; P H Patterson
Journal:  Brain Res Bull       Date:  2001 Oct-Nov 1       Impact factor: 4.077

8.  Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum.

Authors:  L M Mende-Mueller; T Toneff; S R Hwang; M F Chesselet; V Y Hook
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

9.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

10.  The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis.

Authors:  S Holbert; I Denghien; T Kiechle; A Rosenblatt; C Wellington; M R Hayden; R L Margolis; C A Ross; J Dausset; R J Ferrante; C Néri
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

View more
  48 in total

1.  Polyglutamine fibrillogenesis: the pathway unfolds.

Authors:  Christopher A Ross; Michelle A Poirier; Erich E Wanker; Mario Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-30       Impact factor: 11.205

Review 2.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

Review 3.  Polyglutamine misfolding in yeast: toxic and protective aggregation.

Authors:  Martin L Duennwald
Journal:  Prion       Date:  2011-10-01       Impact factor: 3.931

4.  Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Authors:  Xuesong Chen; Jun Wu; Yuan Luo; Xia Liang; Charlene Supnet; Mee Whi Kim; Gregor P Lotz; Guocheng Yang; Paul J Muchowski; Thomas Kodadek; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-09-23

5.  Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis.

Authors:  Jonathan A Sayer; Maria Manczak; Lakshmi Akileswaran; P Hemachandra Reddy; Vincent M Coghlan
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

6.  Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.

Authors:  David W Colby; Yijia Chu; John P Cassady; Martin Duennwald; Helen Zazulak; Jack M Webster; Anne Messer; Susan Lindquist; Vernon Martin Ingram; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-14       Impact factor: 11.205

7.  Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.

Authors:  William J Wolfgang; Todd W Miller; Jack M Webster; James S Huston; Leslie M Thompson; J Lawrence Marsh; Anne Messer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

Review 8.  The ubiquitin-proteasome pathway in Huntington's disease.

Authors:  Steven Finkbeiner; Siddhartha Mitra
Journal:  ScientificWorldJournal       Date:  2008-04-20

9.  Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Authors:  Erik Kvam; Brent L Nannenga; Min S Wang; Zongjian Jia; Michael R Sierks; Anne Messer
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

10.  Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.

Authors:  C Dirk Keene; Cecilia M P Rodrigues; Tacjana Eich; Manik S Chhabra; Clifford J Steer; Walter C Low
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.